Feature | May 20, 2013

Endovascular Repair Of Ruptured Aneurysms Saves More Lives Than Surgery

Ten-year study looks at 106 patients with abdominal aortic aneurysms.

May 20, 2013 — Patients with ruptured abdominal aortic aneurysms (AAA) are more than twice as likely to survive if they have minimally invasive repair than if they have surgery, suggests a 10-year study being.

The aorta is the body’s main artery and about 90 percent of people who suffer from ruptured AAAs bleed to death. Those who make it to the hospital undergo either open surgical repair or minimally invasive treatment with endovascular aneurysm repair (EVAR). 

“Many of these patients are frail, with a variety of health issues, and a minimally invasive solution is by far the best option,” said Sherif Sultan, M.B., M.D., an endovascular surgeon at the University College Hospital Galway, Ireland. “We found 85 percent of patients are suitable for minimally invasive aneurysm repair and in those patients, EVAR should always be the first option.”

The study involved 106 patients who had AAA repair between 2002 and 2012, 75 of whom had open surgery and 31 of whom had EVAR. Overall mortality was higher for surgery patients, with 49 (65 percent) dying within 30 days versus 10 (32 percent) of those who had EVAR. After one year, 12.5 percent of surgery patients were alive versus 56 percent of EVAR patients. Most of the patients died of a co-existing health condition.

AAA is a weakening and ballooning in the aorta, the artery that carries blood from the heart to the rest of the body. AAA is most common in men 65 years or older. Other risk factors include a history of smoking, high blood pressure, high cholesterol and atherosclerosis. The larger the AAA, the more likely it is to rupture. 

Open surgical repair of the aorta involves making a 12-inch incision in the chest and cracking open the ribs to access the aorta. The patient is placed on partial heart-lung bypass, the aorta is clamped off and a fabric graft sewn into place.

EVAR involves threading a collapsed fabric tube, or endograft, through a catheter into a small incision in the groin artery and advancing it through the artery to the site of the tear in the aorta. The endograft is expanded in place, and blood flow is redirected through it, sealing off the tear.

For more information: www.iset.org

Related Content

St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid| October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
ZipLine Medical, Zip Surgical Skin Closure, cath lab time savings, PACE study
News | EP Lab| October 10, 2016
October 10, 2016 — ZipLine Medical Inc.
Mercator MedSystems, Bullfrog Micro-Infusion Device, DANCE trial, VIVA 2016, 13-month results
News | Peripheral Arterial Disease (PAD)| October 07, 2016
Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking...
Keystone Heart, TriGuard Embolic Protection Device, Neuro-TAVR study, brain lesions, American Journal of Cardiology
News | Heart Valve Technology| October 03, 2016
Keystone Heart Ltd. announced data recently published in the American Journal of Cardiology demonstrating new brain...
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
Overlay Init